Citations

Clear

37 citation(s) found for "Anderson, Brian".

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 518-525

10.1097/ju.0000000000003891 | PMID 38421243 Get It

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 509-517

10.1097/ju.0000000000003892 | PMID 38421253 Get It

Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions
Morgan, Todd M. , Boorjian, Stephen A. , Buyyounouski, Mark K. , Chapin, Brian F. , Chen, David Y.T. , Jacene, Heather A. , Kim, Sennett K., Kirkby, Erin, Nathanson, B.J., Posadas, Edwin M. , Morgan, Todd M , Cheng, Heather H. , Chou, Roger , Kamran, Sophia C. , Luckenbaugh, Amy N. , Nathanson, Ben J., Nyame, Yaw A. , Tran, Phuoc T , Chen, Ronald C.

Mayo Clinic

Journal of Urology | February 29, 2024 | Volume: 211 | Issue: 4 | Pages: 526-532

10.1097/ju.0000000000003890 | PMID 38421252 Get It

Health AI Assurance Laboratories—Reply
Anderson, Brian, Shah, Nigam H. , Halamka, John

Mayo Clinic

JAMA | February 12, 2024 | Volume: 331 | Issue: 12 | Pages: 1062

10.1001/jama.2024.1087 | PMID 38345790 Get It

A Nationwide Network of Health AI Assurance Laboratories
Saria, Suchi , Pencina, Michael , Tazbaz, Troy, Tripathi, Micky, Hildahl, Hailey, Anderson, Brian, Shah, Nigam H. , Halamka, John , Callahan, Alison

Mayo Clinic

JAMA | December 20, 2023 | Volume: 331 | Issue: 3 | Pages: 245

10.1001/jama.2023.26930 | PMID 38117493 Get It

Importance Given the importance of rigorous development and evaluation standards needed of artificial intelligence (AI) models used in health care, nationwide accepted procedures to provide assurance that the use of AI is fair, appropriate, valid, effective, and safe are urgently needed. Observations While there are several efforts to develop standards and best practices to evaluate AI, there is a gap between having such guidance and the application of such guidance to both existing and new AI models being developed. As of now, there is no publicly available, nationwide mechanism that enables objective evaluation and ongoing assessment of the consequences of using health AI models in clinical care settings. Conclusion and Relevance The need to create a public-private partnership to support a nationwide health AI assurance labs network is outlined here. In this network, community best practices could be applied for testing health AI models to produce reports on their performance that can be widely shared for managing the lifecycle of AI models over time and across populations and sites where these models are deployed.
Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort
Kiani, Kayvon, Kim, Simon P. , Pessoa, Rodrigo Rodrigues , Gershman, Boris , Gonzalez, Christopher , Molina, Elizabeth, DaSilva, Rodrigo Donalisio, Chapin, Brian F. , Ballon‐Landa, Eric , Molina, Elizabeth, Warren, Adam , DaSilva, Rodrigo Donalisio

Mayo Clinic

Urology Practice | November 2, 2023 | Volume: 11 | Issue: 1 | Pages: 117-122

10.1097/upj.0000000000000476 | PMID 37914379 Get It

Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Barocas, Daniel A. , Bitting, Rhonda L. , Bryce, Alan H. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Guzzo, Thomas, Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Shead, Dorothy A. , Snedeker, Jenna, Freedman-Cass, Deborah A., Bryce, Alan, Bryce, Alan H , Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Netto, George J. , Spratt, Daniel E. , Teply, Benjamin A. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1067-1096

10.6004/jnccn.2023.0050 | PMID 37856213 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
Engel, Brian J. , Paolillo, Vincenzo , Uddin, Md Nasir , Gonzales, Kristyn, McGinnis, Kathryn M., Patnana, Madhavi , Grindel, Brian J., Gores, Gregory J. , Piwnica‐Worms, David , Beretta, Laura , Pisaneschi, Federica , Millward, Steven W. , Gores, Gregory J. , Sutton, Margie N , Piwnica-Worms, David , Beretta, Laura , Pisaneschi, Federica , Gammon, Seth T , Millward, Steven W

Mayo Clinic

Cancers | July 27, 2023 | Volume: 15 | Issue: 15 | Pages: 3787

10.3390/cancers15153787 | PMID 37568603 Get It

The worldwide incidence of hepatocellular carcinoma (HCC) continues to rise, in part due to poor diet, limited exercise, and alcohol abuse. Numerous studies have suggested that the loss or mutation of PTEN plays a critical role in HCC tumorigenesis through the activation of the PI3K/Akt signaling axis. The homozygous knockout of PTEN in the livers of mice results in the accumulation of fat (steatosis), inflammation, fibrosis, and eventually progression to HCC. This phenotype bears a striking similarity to non-alcoholic steatohepatitis (NASH) which is thought to occupy an intermediate stage between non-alcoholic fatty liver disease (NAFLD), fibrosis, and HCC. The molecular and physiological phenotypes that manifest during the transition to HCC suggest that molecular imaging could provide a non-invasive screening platform to identify the hallmarks of HCC initiation prior to the presentation of clinical disease. We have carried out longitudinal imaging studies on the liver-specific PTEN knockout mouse model using CT, MRI, and multi-tracer PET to interrogate liver size, steatosis, inflammation, and apoptosis. In male PTEN knockout mice, significant steatosis was observed as early as 3 months using both magnetic resonance spectroscopy (MRS) and computed tomography (CT). Enhanced uptake of the apoptosis tracer 18F-TBD was also observed in the livers of male PTEN homozygous knockout mice between 3 and 4 months of age relative to heterozygous knockout controls. Liver uptake of the inflammation tracer [18F]4FN remained relatively low and constant over 7 months in male PTEN homozygous knockout mice, suggesting the suppression of high-energy ROS/RNS with PTEN deletion relative to heterozygous males where the [18F]4FN liver uptake was elevated at early and late time points. All male PTEN homozygous mice developed HCC lesions by month 10. In contrast to the male cohort, only 20% (2 out of 10) of female PTEN homozygous knockout mice developed HCC lesions by month 10. Steatosis was significantly less pronounced in the female PTEN homozygous knockout mice relative to males and could not accurately predict the eventual occurrence of HCC. As with the males, the [18F]4FN uptake in female PTEN homozygous knockout mice was low and constant throughout the time course. The liver uptake of 18F-TBD at 3 and 4.5 months was higher in the two female PTEN knockout mice that would eventually develop HCC and was the most predictive imaging biomarker for HCC in the female cohort. These studies demonstrate the diagnostic and prognostic role of multi-modal imaging in HCC mouse models and provide compelling evidence that disease progression in the PTEN knockout model is highly dependent on gender.
Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer
Andrews, Jack R. , Sood, Akshay, Chapin, Brian F. , Sood, Akshay

Mayo Clinic

Journal of Urology | May 17, 2023 | Volume: 210 | Issue: 2 | Pages: 242-243

10.1097/ju.0000000000003495 | PMID 37194136 Get It

Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
Ambrose, Nalini, Anderson, Brian, Barrera-Oro, Julio, Campion, Francis X. , Danan, Risa, D’Arinzo, Lauren , Drews, Ashley, Erlandson, Karl J. , Fitzgerald, Kristin , García, Melissa, Gong, Carlene, Hanna, George J. , Lopansri, Bert K. , Musser, James M. , Piantadosi, Steven , Pritt, Bobbi S. , Roberts, Seth, Sandmeyer, Suzanne , Stein, David , Webb, Brandon , Yttri, Jennifer, O'horo, John, Pritt, Bobbi, Pritt, Bobbi S , Amin, Alpesh , Bertagnolli, Monica M. , Chow, Daniel S. , Gaspar, Fraser W. , Jones, Stephen L. , O’Horo, John C. , Razonable, Raymund R. , Vahidy, Farhaan S

Mayo Clinic

JAMA Network Open | April 24, 2023 | Volume: 6 | Issue: 4 | Pages: e239694

10.1001/jamanetworkopen.2023.9694 | PMID 37093599 Get It

ImportanceEvidence on the effectiveness and safety of COVID-19 therapies across a diverse population with varied risk factors is needed to inform clinical practice.ObjectiveTo assess the safety of neutralizing monoclonal antibodies (nMAbs) for the treatment of COVID-19 and their association with adverse outcomes.Design, Setting, and ParticipantsThis retrospective cohort study included 167 183 patients from a consortium of 4 health care systems based in California, Minnesota, Texas, and Utah. The study included nonhospitalized patients 12 years and older with a positive COVID-19 laboratory test collected between November 9, 2020, and January 31, 2022, who met at least 1 emergency use authorization criterion for risk of a poor outcome.ExposureFour nMAb products (bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab) administered in the outpatient setting.Main Outcomes and MeasuresClinical and SARS-CoV-2 genomic sequence data and propensity-adjusted marginal structural models were used to assess the association between treatment with nMAbs and 4 outcomes: all-cause emergency department (ED) visits, hospitalization, death, and a composite of hospitalization or death within 14 days and 30 days of the index date (defined as the date of the first positive COVID-19 test or the date of referral). Patient index dates were categorized into 4 variant epochs: pre-Delta (November 9, 2020, to June 30, 2021), Delta (July 1 to November 30, 2021), Delta and Omicron BA.1 (December 1 to 31, 2021), and Omicron BA.1 (January 1 to 31, 2022).ResultsAmong 167 183 patients, the mean (SD) age was 47.0 (18.5) years; 95 669 patients (57.2%) were female at birth, 139 379 (83.4%) were White, and 138 900 (83.1%) were non-Hispanic. A total of 25 241 patients received treatment with nMAbs. Treatment with nMAbs was associated with lower odds of ED visits within 14 days (odds ratio [OR], 0.76; 95% CI, 0.68-0.85), hospitalization within 14 days (OR, 0.52; 95% CI, 0.45-0.59), and death within 30 days (OR, 0.14; 95% CI, 0.10-0.20). The association between nMAbs and reduced risk of hospitalization was stronger in unvaccinated patients (14-day hospitalization: OR, 0.51; 95% CI, 0.44-0.59), and the associations with hospitalization and death were stronger in immunocompromised patients (hospitalization within 14 days: OR, 0.31 [95% CI, 0.24-0.41]; death within 30 days: OR, 0.13 [95% CI, 0.06-0.27]). The strength of associations of nMAbs increased incrementally among patients with a greater probability of poor outcomes; for example, the ORs for hospitalization within 14 days were 0.58 (95% CI, 0.48-0.72) among those in the third (moderate) risk stratum and 0.41 (95% CI, 0.32-0.53) among those in the fifth (highest) risk stratum. The association of nMAb treatment with reduced risk of hospitalizations within 14 days was strongest during the Delta variant epoch (OR, 0.37; 95% CI, 0.31-0.43) but not during the Omicron BA.1 epoch (OR, 1.29; 95% CI, 0.68-2.47). These findings were corroborated in the subset of patients with viral genomic data. Treatment with nMAbs was associated with a significant mortality benefit in all variant epochs (pre-Delta: OR, 0.16 [95% CI, 0.08-0.33]; Delta: OR, 0.14 [95% CI, 0.09-0.22]; Delta and Omicron BA.1: OR, 0.10 [95% CI, 0.03-0.35]; and Omicron BA.1: OR, 0.13 [95% CI, 0.02-0.93]). Potential adverse drug events were identified in 38 treated patients (0.2%).Conclusions and RelevanceIn this study, nMAb treatment for COVID-19 was safe and associated with reductions in ED visits, hospitalization, and death, although it was not associated with reduced risk of hospitalization during the Omicron BA.1 epoch. These findings suggest that targeted risk stratification strategies may help optimize future nMAb treatment decisions.